Arrowhead Pharmaceuticals (ARWR) Capital Expenditures Growth (5y) (2016 - 2026)
Arrowhead Pharmaceuticals (ARWR) Capital Expenditures Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Arrowhead Pharmaceuticals | 12.26 Bn | 10.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.57% |
| Dec 31, 2025 | -12.84% |
| Sep 30, 2025 | -15.29% |
| Jun 30, 2025 | -50.93% |
| Mar 31, 2025 | 23.19% |
| Dec 31, 2024 | -9.84% |
| Jun 30, 2024 | 28.21% |
| Mar 31, 2024 | 104.76% |
| Dec 31, 2023 | 147.62% |
| Jun 30, 2023 | -203.49% |
| Mar 31, 2023 | 135.35% |
| Dec 31, 2022 | 210.23% |
| Sep 30, 2022 | 213.84% |
| Jun 30, 2022 | 52.46% |
| Mar 31, 2022 | 28.50% |
| Dec 31, 2021 | 1.75% |
| Sep 30, 2021 | 24.76% |
| Jun 30, 2021 | 43.45% |
| Mar 31, 2021 | 137.91% |
| Dec 31, 2020 | 60.06% |